Efficacy markers in depression.
Current antidepressant agents are similar in efficacy to the original drugs discovered in the 1950s. The development of new treatments for depression is, however, limited by the absence of validated human biomarker models to predict efficacy, clinical profile and dosing. Such models need to meet key...
Hoofdauteurs: | Harmer, C, Cowen, P, Goodwin, G |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
2011
|
Gelijkaardige items
-
Efficacy markers in depression
door: Harmer, C, et al.
Gepubliceerd in: (2011) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms.
door: Hayward, G, et al.
Gepubliceerd in: (2005) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms
door: Hayward, G, et al.
Gepubliceerd in: (2005) -
Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression.
door: Bhagwagar, Z, et al.
Gepubliceerd in: (2004) -
Elevated waking cortisol levels in neuroticism: A biological vulnerability factor for depressive disorders?
door: Portella, M, et al.
Gepubliceerd in: (2004)